tradingkey.logo
tradingkey.logo
Search

ADMA Biologics Inc

ADMA
Add to Watchlist
8.610USD
+0.240+2.87%
Close 07/01, 16:00ETQuotes delayed by 15 min
2.00BMarket Cap
12.38P/E TTM

More Details of ADMA Biologics Inc Company

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

ADMA Biologics Inc Info

Ticker SymbolADMA
Company nameADMA Biologics Inc
IPO dateOct 17, 2013
CEOGrossman (Adam S)
Number of employees677
Security typeOrdinary Share
Fiscal year-endOct 17
Address465 State Route 17
CityRAMSEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07446
Phone12014785552
Websitehttps://www.admabiologics.com/
Ticker SymbolADMA
IPO dateOct 17, 2013
CEOGrossman (Adam S)

Company Executives of ADMA Biologics Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%
Dr. Young T. Kwon, Ph.D.
Dr. Young T. Kwon, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison C. Finger
Ms. Alison C. Finger
Independent Director
Independent Director
--
--
Ms. Kaitlin Kestenberg
Ms. Kaitlin Kestenberg
Chief Operating Officer, Senior Vice President - Compliance
Chief Operating Officer, Senior Vice President - Compliance
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%

FAQs

Who are the top five shareholders of ADMA Biologics Inc?

The top five shareholders of ADMA Biologics Inc are: Mr. Adam S. Grossman

How many institutions hold shares of ADMA Biologics Inc (ADMA)?

As of 2026Q1, 784 institutions hold shares of ADMA Biologics Inc, with a combined market value of approximately 218.01M, accounting for 94.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -33855143.00.